Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
10 10 2023
Historique:
received: 18 10 2022
revised: 27 02 2023
accepted: 08 09 2023
medline: 23 10 2023
pubmed: 18 9 2023
entrez: 18 9 2023
Statut: ppublish

Résumé

Intraductal papillary mucinous neoplasms (IPMN) are cystic precursor lesions to pancreatic ductal adenocarcinoma (PDAC). IPMNs undergo multistep progression from low-grade (LG) to high-grade (HG) dysplasia, culminating in invasive neoplasia. While patterns of IPMN progression have been analyzed using multiregion sequencing for somatic mutations, there is no integrated assessment of molecular events, including copy-number alterations (CNA) and transcriptional changes that accompany IPMN progression. We performed laser capture microdissection on surgically resected IPMNs of varying grades of histologic dysplasia obtained from 23 patients, followed by whole-exome and whole-transcriptome sequencing. Overall, HG IPMNs displayed a significantly greater aneuploidy score than LG lesions, with chromosome 1q amplification being associated with HG progression and with cases that harbored co-occurring PDAC. Furthermore, the combined assessment of single-nucleotide variants (SNV) and CNAs identified both linear and branched evolutionary trajectories, underscoring the heterogeneity in the progression of LG lesions to HG and PDAC. At the transcriptome level, upregulation of MYC-regulated targets and downregulation of transcripts associated with the MHC class I antigen presentation machinery as well as pathways related to glycosylation were a common feature of progression to HG. In addition, the established PDAC transcriptional subtypes (basal-like and classical) were readily apparent within IPMNs. Taken together, this work emphasizes the role of 1q copy-number amplification as a putative biomarker of high-risk IPMNs, underscores the importance of immune evasion even in noninvasive precursor lesions, and reinforces that evolutionary pathways in IPMNs are heterogenous, comprised of both SNV and CNA-driven events. Integrated molecular analysis of genomic and transcriptomic alterations in the multistep progression of IPMNs, which are bona fide precursors of pancreatic cancer, identifies features associated with progression of low-risk lesions to high-risk lesions and cancer, which might enable patient stratification and cancer interception strategies.

Identifiants

pubmed: 37721516
pii: 729107
doi: 10.1158/2767-9764.CRC-22-0419
pmc: PMC10563795
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2062-2073

Subventions

Organisme : NIH HHS
ID : U54CA274371
Pays : United States
Organisme : NIH HHS
ID : P50CA221707
Pays : United States
Organisme : NIH HHS
ID : U54CA096300
Pays : United States
Organisme : NIH HHS
ID : U54CA096297
Pays : United States
Organisme : NIH HHS
ID : T32CA217789
Pays : United States
Organisme : NIH HHS
ID : T32CA009599
Pays : United States
Organisme : NIH HHS
ID : UO1CA214263
Pays : United States
Organisme : NIH HHS
ID : U01CA196403
Pays : United States
Organisme : NIH HHS
ID : U01CA200468
Pays : United States
Organisme : NIH HHS
ID : K22CA258678
Pays : United States
Organisme : NIH HHS
ID : R21CA273974-01
Pays : United States
Organisme : NIH HHS
ID : U01CA196406
Pays : United States
Organisme : NIH HHS
ID : U01CA196406-03S1
Pays : United States
Organisme : NIH HHS
ID : T32GM008806
Pays : United States
Organisme : NIH HHS
ID : T15LM011271
Pays : United States
Organisme : NIH HHS
ID : P30CA042014
Pays : United States

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Auteurs

Alexander Semaan (A)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Vincent Bernard (V)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Justin Wong (J)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Yuki Makino (Y)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Daniel B Swartzlander (DB)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kimal I Rajapakshe (KI)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jaewon J Lee (JJ)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Adam Officer (A)

Bioinformatics and Systems Biology Graduate Program and Moores Cancer Center, University of California San Diego School of Medicine, San Diego, California.

Christian Max Schmidt (CM)

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.

Howard H Wu (HH)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

Courtney L Scaife (CL)

Department of Surgery, University of Utah, Salt Lake City, Utah.

Kajsa E Affolter (KE)

Department of Pathology, University of Utah, Salt Lake City, Utah.

Daniela Nachmanson (D)

Bioinformatics and Systems Biology Graduate Program and Moores Cancer Center, University of California San Diego School of Medicine, San Diego, California.

Matthew A Firpo (MA)

Department of Surgery, University of Utah, Salt Lake City, Utah.

Michele Yip-Schneider (M)

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.

Andrew M Lowy (AM)

Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California.

Olivier Harismendy (O)

Bioinformatics and Systems Biology Graduate Program and Moores Cancer Center, University of California San Diego School of Medicine, San Diego, California.

Subrata Sen (S)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Anirban Maitra (A)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Yasminka A Jakubek (YA)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Paola A Guerrero (PA)

Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH